CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

CUDC-907 is a first-in-class, oral small molecule inhibitor of both HDAC (class I and II) and PI3K (class Iα, β, and δ) enzymes, with demonstrated anti-tumor activity in multiple pre-clinical models, including MYC-driven ones. In this report, we present the safety and preliminary activity results of...

Descripción completa

Detalles Bibliográficos
Autores principales: Oki, Yasuhiro, Kelly, Kevin R, Flinn, Ian, Patel, Manish R., Gharavi, Robert, Ma, Anna, Parker, Jefferson, Hafeez, Amir, Tuck, David, Younes, Anas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664396/
https://www.ncbi.nlm.nih.gov/pubmed/28860342
http://dx.doi.org/10.3324/haematol.2017.172882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664396/
https://www.ncbi.nlm.nih.gov/pubmed/28860342
http://dx.doi.org/10.3324/haematol.2017.172882

Ejemplares similares